Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

490.18 +6.15 (+1.27%)

Streaming Delayed Price Updated: 11:57 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

75 76 Next >

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 ↗

April 11, 2024

In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.

Via InvestorPlace

Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock ↗

April 11, 2024

Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.

Via InvestorPlace

Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts ↗

April 11, 2024

An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack.

Via InvestorPlace

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗

April 11, 2024

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Via InvestorPlace

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗

April 11, 2024

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Via Investor's Business Daily

Vertex Pharmaceuticals: Buy, Sell, or Hold? ↗

April 11, 2024

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?

Via The Motley Fool

1 Top Growth Stock to Buy and Hold Forever ↗

March 31, 2024

This drugmaker looks unstoppable.

Via The Motley Fool

If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today ↗

March 25, 2024

Via Benzinga

Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune ↗

April 11, 2024

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to...

Via Benzinga

Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity' ↗

April 11, 2024

The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons

Via Benzinga

Topics Economy

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal ↗

April 10, 2024

The companies expect the deal to close later this quarter.

Via Investor's Business Daily

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

April 10, 2024

From Alpine Immune Sciences, Inc.

Via Business Wire

Vertex to Announce First Quarter 2024 Financial Results on May 6

April 09, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy? ↗

April 09, 2024

This innovative machine rolls on.

Via The Motley Fool

Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' ↗

April 09, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over

Via Benzinga

3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April ↗

April 09, 2024

These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.

Via InvestorPlace

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

April 09, 2024

These companies are close to launching new products that could supercharge revenue.

Via The Motley Fool

Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul ↗

April 05, 2024

These businesses are booming.

Via The Motley Fool

Biotech Sector Nears Breakout: Will it Outperform in Q2?

April 03, 2024

The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains

Via MarketBeat

Topics ETFs

Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead ↗

April 01, 2024

All three companies have very long runways for growth ahead.

Via The Motley Fool

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

April 01, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Meet The "Magnificent Seven" of Healthcare Stocks ↗

April 01, 2024

The tech sector doesn't have a monopoly on magnificent corporations.

Via The Motley Fool

2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years ↗

March 31, 2024

Great businesses are here to stay. These are two excellent examples.

Via The Motley Fool

3 Unstoppable Stocks to Buy Hand Over Fist in April ↗

March 30, 2024

These stocks have exceptionally bright prospects.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 28, 2024

Via Benzinga

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why ↗

March 28, 2024

The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.

Via Investor's Business Daily

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”

March 25, 2024

Via AB Newswire

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

March 21, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.